Is United Therapeutics Corporation (UTHR) Going to Burn These Hedge Funds?

Page 1 of 2

United Therapeutics Corporation (NASDAQ:UTHR) shareholders have witnessed a decrease in hedge fund interest of late.

United Therapeutics Corporation (NASDAQ:UTHR)If you’d ask most investors, hedge funds are perceived as slow, old investment tools of the past. While there are greater than 8000 funds trading today, we choose to focus on the moguls of this club, close to 450 funds. It is widely believed that this group controls most of the hedge fund industry’s total asset base, and by paying attention to their highest performing equity investments, we have deciphered a number of investment strategies that have historically outstripped Mr. Market. Our small-cap hedge fund strategy outperformed the S&P 500 index by 18 percentage points annually for a decade in our back tests, and since we’ve started sharing our picks with our subscribers at the end of August 2012, we have outclassed the S&P 500 index by 23.3 percentage points in 8 months (check out a sample of our picks).

Just as important, optimistic insider trading activity is another way to break down the marketplace. As the old adage goes: there are many stimuli for an upper level exec to downsize shares of his or her company, but only one, very clear reason why they would initiate a purchase. Several academic studies have demonstrated the impressive potential of this tactic if piggybackers understand what to do (learn more here).

Keeping this in mind, we’re going to take a glance at the key action surrounding United Therapeutics Corporation (NASDAQ:UTHR).

What have hedge funds been doing with United Therapeutics Corporation (NASDAQ:UTHR)?

In preparation for this quarter, a total of 13 of the hedge funds we track were long in this stock, a change of -24% from the previous quarter. With hedgies’ capital changing hands, there exists an “upper tier” of noteworthy hedge fund managers who were upping their stakes meaningfully.

Of the funds we track, Sectoral Asset Management, managed by Jerome Pfund and Michael Sjostrom, holds the most valuable position in United Therapeutics Corporation (NASDAQ:UTHR). Sectoral Asset Management has a $72.1 million position in the stock, comprising 2.2% of its 13F portfolio. Sitting at the No. 2 spot is Palo Alto Investors, managed by William Leland Edwards, which held a $54.6 million position; the fund has 6.5% of its 13F portfolio invested in the stock. Remaining hedge funds with similar optimism include Jim Simons’s Renaissance Technologies, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital and Joel Greenblatt’s Gotham Asset Management.

Because United Therapeutics Corporation (NASDAQ:UTHR) has witnessed falling interest from the smart money, we can see that there is a sect of hedgies who sold off their entire stakes at the end of the first quarter. At the top of the heap, Matt Sirovich and Jeremy Mindich’s Scopia Capital dropped the biggest stake of the 450+ funds we monitor, valued at close to $33.2 million in stock., and Daniel Arbess of Xerion was right behind this move, as the fund dumped about $8.8 million worth. These bearish behaviors are important to note, as aggregate hedge fund interest was cut by 4 funds at the end of the first quarter.

How have insiders been trading United Therapeutics Corporation (NASDAQ:UTHR)?

Insider purchases made by high-level executives is particularly usable when the primary stock in question has seen transactions within the past six months. Over the latest half-year time period, United Therapeutics Corporation (NASDAQ:UTHR) has experienced 1 unique insiders buying, and 7 insider sales (see the details of insider trades here).

Let’s also review hedge fund and insider activity in other stocks similar to United Therapeutics Corporation (NASDAQ:UTHR). These stocks are The Medicines Company (NASDAQ:MDCO), Taro Pharmaceutical Industries Ltd. (NYSE:TARO), Endo Health Solutions Inc (NASDAQ:ENDP), Warner Chilcott Plc (NASDAQ:WCRX), and Cubist Pharmaceuticals Inc (NASDAQ:CBST). All of these stocks are in the drug manufacturers – other industry and their market caps resemble UTHR’s market cap.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!